title: A multi-domain protein for beta1 integrin-targeted DNA delivery.
abstract: The development of effective receptor-targeted nonviral vectors for use in vivo is complicated by a number of technical problems. One of these is the low efficiency of the conjugation procedures used to couple protein ligands to the DNA condensing carrier molecules. We have made and characterized a multi-domain protein (SPKR)4inv, that is designed to target plasmid DNA to beta1 integrins in remodeling tissue. It contains a nonspecific DNA-binding domain (SPKR)4, a rigid alpha-helical linker, and the C-terminal beta1 integrin binding domain (aa 793-987) of the Yersinia pseudotuberculosis invasin protein. (SPKR)4inv could be purified at high yields using a bacterial expression system. We show that (SPKR)4inv binds with high affinity to both plasmid DNA and beta1 integrins. In a cell attachment assay, the apparent affinity of (SPKR)4inv for beta1 integrins is three orders of magnitude higher than that of the synthetic peptide integrin ligand RGDS. (SPKR)4inv-plasmid complexes are not active in an in vitro transfection assay. However, transfection efficiencies of plasmid complexes with a cationic lipid micelle (DOTAP/Tween-20) or a cationic polymer (polyethylenimine), are significantly increased in combination with (SPKR)4inv. (SPKR)4inv-mediated transfection can be inhibited by a soluble form of beta1 integrin, which is evidence for its receptor specificity. In conclusion, (SPKR)4inv allows beta1 integrin-specific targeting of plasmid-carrier complexes, while avoiding inefficient and cumbersome coupling chemistry. The modular design of the expression vector allows production of similar multi-domain proteins with a different affinity. The further development of such complexes for use in vivo is discussed.
authors.affiliation: Department of Cell Biology, Erasmus University, Rotterdam, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Fortunati
authors.forename: E
authors.initials: E
authors.lastname: Ehlert
authors.forename: N D
authors.initials: ND
authors.lastname: van Loo
authors.forename: C
authors.initials: C
authors.lastname: Wyman
authors.forename: J A
authors.initials: JA
authors.lastname: Eble
authors.forename: F
authors.initials: F
authors.lastname: Grosveld
authors.forename: B J
authors.initials: BJ
authors.lastname: Scholte
mesh_terms: D000937:Antigen-Antibody Reactions; D005229:Fatty Acids, Monounsaturated; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000378:metabolism*; D006801:Humans; D019012:Integrin beta1 / Q000378:metabolism*; D010957:Plasmids / Q000378:metabolism; D011094:Polyethyleneimine; D011485:Protein Binding; D000644:Quaternary Ammonium Compounds; D014162:Transfection / Q000379:methods*; D014407:Tumor Cells, Cultured; D015011:Yersinia pseudotuberculosis / Q000235:genetics*
chemical_list: D005229:Fatty Acids, Monounsaturated; D019012:Integrin beta1; D000644:Quaternary Ammonium Compounds; D011094:Polyethyleneimine; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane